Light-Responsive conjugated polymer nanoparticles with Spatial-Controlled camptothecin release via ？？？π stacking for improved Combinatorial therapy of breast cancer

Release time:2025-02-16

Impact Factor:8.0

DOI number:10.1016/j.matdes.2024.113270

Affiliation of Author(s):Xiangya School of Pharmaceutical Sciences in Central South University, Changsha, Hunan, China

Journal:Materials & Design

Place of Publication:英国

Key Words:Drug deliveryConjugated PolymerPhotothermal effectSpatial-ControlledCombinational Therapy

Abstract:The treatment of breast cancer (BC) remains a significant challenge, exemplified by the limitations of chemotherapy due to its high side effects. Light-responsive drug delivery systems (DDS) offer a promising approach to spatially and temporally release drugs, minimizing chemotherapy side effects and enhancing efficacy. However, achieving precise delivery and site-specific drug release poses complex challenges. Here, We present a novel nano-system combining light-responsive photothermal therapy (PTT) with photothermal-responsive chemotherapy via π − π Stacking. Conjugated polymer nanoparticles (cRGD-PTer N25/CPT NPs) is designed for spatiotemporal targeted PTT/chemotherapy. Research shows that the strong near-infrared absorption of PTer N25 endows cRGD-PTer N25/CPT NPs with excellent photothermal capabilities(57.4 %) and near-infrared laser-triggered drug release performance. The cRGD-PTer N25/CPT NPs enhanced BC-specific cellular accumulation, prolonged blood circulation, exhibited good biocompatibility, and improved PTT and chemotherapy efficacy in BC cell lines and mouse models while reducing systemic toxicity. The photothermal effect triggered the on-demand release of camptothecin (CPT), producing therapeutic effects and downregulating heat shock protein 70 (HSP 70), reducing cancer cell thermoresistance, and enhancing combined treatment efficacy. Under spatial and temporal control, the tumor growth inhibition rate of the cRGD-PTer N25/CPT NPs group reached 93.6 %, nearly eradicating tumor presence, whereas the control group exhibited only partial inhibition. Minimal cardiotoxicity and metastatic side effects are not observed. This work presents a viable strategy for designing novel controlled-release drug systems to improve breast cancer treatment efficiency.

Co-author:J. Tian, W. Xu, H. Liu, D. Xiang

First Author:Z. Zeng

Indexed by:Journal paper

Correspondence Author:D. Liao, J. Wu, C. Chen

Discipline:Medicine

First-Level Discipline:Pharmaceutical Science

Document Type:电子版

Volume:245

Page Number:113270

ISSN No.:1873-4197

Translation or Not:no

Date of Publication:2024-08-27